Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
Follow CLSDQ
Clearside Biomedical, Inc. (CLSDQ) Piotroski F-score
Clearside Biomedical, Inc.'s Piotroski F-score for fiscal 2024 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 3 | (1.00) |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | (3.00) |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | 0.00 |
| FY2019 | 4 | 2.00 |
| FY2018 | 2 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (116.16%) | (76.15%) | Fail | 0 |
| Positive operating cash flow | (24.70m) | (18.13m) | Fail | 0 |
| Rising return on assets | (116.16%) | (76.15%) | Fail | 0 |
| Cash flow above net income | 9.65m | 14.35m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 4.44 | 4.42 | Pass | 1 |
| No new shares issued | 4,922,700 | 4,122,500 | Fail | 0 |
| Rising gross margin | 91.05% | 95.68% | Fail | 0 |
| Rising asset turnover | 0.06 | 0.19 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| VRAX Virax Biolabs Group Limited compare | 6 |
| WINT Windtree Therapeutics, Inc. compare | 5 |
| BRTX Biorestorative Therapies, Inc. compare | 4 |
| CLSDQ Clearside Biomedical, Inc. | 3 |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | 2 |
| OGEN Oragenics, Inc. compare | 2 |
| MTNB Matinas Biopharma Holdings, Inc. compare | 1 |
| KAPA Kairos Pharma, Ltd. compare | — |
| BPTSY Biophytis SA Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover